Aventis Pharma Deutschland, Gmbh

Sunil Kumar Deshmukh

Michael Kurz

Herbert Kogler

Nirogi Venkata Satya Ramakrishna

Mythili Raman

Dietmar Schummer

Erra Koteswara Satya Vijaya Kumar

Swati Dhananjay Tare

Sridevi Kota

Manoj Maniram Singh Kushwaha

Keshavapura Hosamane Sreedhara Swamy

The present invention relates to a compound named Mumbaistatin, its pharmaceutically acceptable salts and derivatives, a process for its production, and its use as a pharmaceutical. Mumbaistatin is obtainable by cultivation of the microorganism HIL-008003 (DSM 11641). Mumbaistatin is a glucose-6-phosphate translocase inhibitor and can be used in the treatment of diabetes mellitus. The present invention further relates to a process for the production of Mumbaistatin, to the microorganism HIL-008003 (DSM 11641), to the use of Mumbaistatin and its pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use in the treatment of diabetes mellitus, and to pharmaceutical compositions comprising Mumbaistatin or a pharmaceutically acceptable salt or derivative thereof.

Mumbaistatin, a process for it's production and its use as a pharmaceutical

Growing community of inventors

Maharashtra, India

Sunil Kumar Deshmukh